Ellen M. Dobrusin

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

David W. Fry, Alexander J. Bridges, William A. Denny et al. · Proceedings of the National Academy of Sciences · 1998 · 417 citations

Drug Target, Cell Growth, Chemical Biology +21

Substrate specificity of the protein tyrosine phosphatases.

Z.Y. Zhang, Andrea M. Thieme-Sefler, Derek Maclean et al. · Proceedings of the National Academy of Sciences · 1993 · 192 citations · Full text

Protein Function, Signal Transduction, Biochemistry +13

Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)pyrido[<i>d</i>]pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor

Jeff B. Smaill, Brian D. Palmer, Gordon W. Rewcastle et al. · Journal of Medicinal Chemistry · 1999 · 178 citations · Full text

Pyrido[2,3-<i>d</i>]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4

Scott N. VanderWel, Patricia J. Harvey, Dennis J. McNamara et al. · Journal of Medicinal Chemistry · 2005 · 148 citations · Full text

Medicinal Chemistry, Drug Target, Excellent Selectivity +14

Structure-Based Design of a Potent, Selective, and Irreversible Inhibitor of the Catalytic Domain of the erbB Receptor Subfamily of Protein Tyrosine Kinases

Juswinder Singh, Ellen M. Dobrusin, David W. Fry et al. · Journal of Medicinal Chemistry · 1997 · 107 citations · Full text

Catalytic Domain, Engineering, Biomolecular Structure Prediction +21